Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 11:35 UTC. Details in the imprint.
Johnson & Johnson (US4781601046) heads into the new trading week with a fresh analyst upgrade and a recent pullback in the share price. Leerink recently raised its rating on the healthcare group to Outperform from Market Perform and lifted its price target to $265 from $252, according to an analyst summary based on a Leerink update cited by Intellectia.
Go deeper
All news and analysis on Johnson & Johnson stock
From analyst calls to regulatory headlines, Johnson & Johnson stock regularly moves on news from Wall Street and the healthcare sector.
What the Leerink upgrade signals
According to a recent summary of Wall Street actions, Leerink upgraded Johnson & Johnson to Outperform from Market Perform and increased its price target to $265 from $252, highlighting the stock as a more stable alternative to richly valued tech names.
The move adds a supportive voice to the broader analyst community ahead of the next earnings update, even as the shares have come under short-term pressure. Retail investors now face a mix of softer near-term trading and firmer longer-term analyst conviction.
Sunday focus on background and positioning
On Sunday, the angle is less about intraday moves and more about how Johnson & Johnson positions itself in portfolios as a global healthcare blue chip. The group combines pharmaceuticals, medical technology and consumer health heritage after the Kenvue spin-off.
For many investors, the stock functions as a defensive anchor in the Standard & Poor’s 500 index, with exposure to therapeutic areas like immunology and oncology as well as surgical robotics and other devices.
The product behind the stock
Johnson & Johnson generates a substantial part of its revenue with prescription medicines such as the multiple myeloma drug Darzalex and the plaque psoriasis therapy Tremfya, alongside its MedTech portfolio ranging from electrophysiology catheters to orthopedics implants.
Where the stock trades today
Johnson & Johnson shares (US4781601046) last closed on the New York Stock Exchange at $228.39 on 06/20/2026, according to recent market data in US dollars.
Key facts on Johnson & Johnson stock
- Company: Johnson & Johnson Inc.
- ISIN: US4781601046
- WKN: 853260
- Ticker: JNJ
- Venue: NYSE
- Price (as of 06/20/2026, 21:30 UTC): 228.39 USD
- Market cap: 440,000,000,000 USD (as of 06/20/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Medical Devices
- Index membership: Dow Jones Industrial Average, S&P 500
- Next earnings date: 07/18/2026
More on Johnson & Johnson stock on social media
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
